| |
Univariate analysis
|
Multivariate analysis
|
|---|
|
Variable
|
OR
|
95% CI
|
P value
|
OR
|
95% CI
|
P value
|
|---|
|
Age (years)
|
1.075
|
1.054–1.097
|
< .0001*
|
1.103
|
1.073—1.134
|
< .0001*
|
|
Men /Women (n)
|
1.158
|
0.753–1.782
|
0.5037
| | | |
|
Type 2 diabetes (n)
|
2.532
|
1.412–4.545
|
0.0018*
| | | |
|
Dyslipidemia (n)
|
2.188
|
1.195–4.000
|
0.0112*
| | | |
|
High-blood pressure (n)
|
2.976
|
1.859–4.762
|
< .0001*
| | | |
|
Obesity (BMI ≥ 30) (n)
|
1.086
|
0.674–1.748
|
0.7358
| | | |
|
Metabolic syndrome (n)
|
2.299
|
1.294–4.082
|
0.0046*
| | | |
|
Hypothyroidism (n)
|
1.869
|
0.999–3.497
|
0.0504
| | | |
|
Previous alcohol use (n)
|
1.089
|
0.493–2.404
|
0.8325
| | | |
|
HOMA-IR value ≥ 2.5 (n)
|
1.773
|
1.149–2.732
|
0.0096*
| | | |
|
AST (U/L)
|
1.025
|
1.016–1.034
|
< .0001*
| | | |
|
ALT (U/L)
|
1.025
|
1.017–1.033
|
< .0001*
|
1.028
|
1.017–1.038
|
< .0001*
|
|
Alkaline phosphatase (U/L)
|
1.029
|
1.018–1.040
|
< .0001*
|
1.019
|
1.006–1.032
|
0.0043*
|
|
GGT (U/L)
|
1.007
|
1.003–1.010
|
< .0001*
| | | |
|
Creatinine (mg/dL)
|
1.183
|
0.720–1.943
|
0.5065
| | | |
|
Total cholesterol (mg/dL)
|
0.988
|
0.982–0.995
|
0.0002*
|
0.975
|
0.965–0.984
|
< .0001*
|
|
HDL (mg/dL)
|
0.993
|
0.980–1.006
|
0.2949
| | | |
|
LDL (mg/dL)
|
0.987
|
0.980–0.994
|
0.0004*
| | | |
|
Triglycerides (mg/dL)
|
0.997
|
0.993–1.001
|
0.1454
| | | |
|
PNPLA3 C / G allele (n)
|
1.013
|
0.659–1.557
|
0.9524
| | | |
|
TM6SF2 CT + TT / CC (n)
|
1.953
|
1.009–3.788
|
0.0471*
| | | |
- Logistic regression
- ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; CI: confidence interval; GGT: gamma glutamyl transferase; HCV: hepatitis C virus; HDL: high-density lipoprotein; HOMA-IR: Homeostatic Model of Assessment; LDL: low-density lipoprotein; OR: odds ratio
- *p value < 0.05
